Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
City of Hope Medical Center
Nurix Therapeutics, Inc.
Verismo Therapeutics
Calibr, a division of Scripps Research
Novartis
AbbVie
Ohio State University Comprehensive Cancer Center
Nurix Therapeutics, Inc.
MEI Pharma, Inc.
Massachusetts General Hospital
BeOne Medicines
Eli Lilly and Company
Medical College of Wisconsin
Ascentage Pharma Group Inc.
Newave Pharmaceutical Inc
Schrödinger, Inc.
Mayo Clinic
LTZ Therapeutics, Inc.
Prelude Therapeutics
AbbVie
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco
City of Hope Medical Center
Century Therapeutics, Inc.
Carna Biosciences, Inc.
Sana Biotechnology
National Cancer Institute (NCI)
City of Hope Medical Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University of Arizona
Case Comprehensive Cancer Center
Mayo Clinic
City of Hope Medical Center
City of Hope Medical Center
Accutar Biotechnology Inc
Sana Biotechnology
Thomas Jefferson University
University of Maryland, Baltimore
Boryung Pharmaceutical Co., Ltd
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Acepodia Biotech, Inc.
Stanford University
Adicet Therapeutics
Peking University Cancer Hospital & Institute
Mayo Clinic
University of California, Davis
Bio-Path Holdings, Inc.